NCT06385886 Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
| NCT ID | NCT06385886 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RTI International |
| Condition | Sickle Cell Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-06-08 |
| Primary Completion | 2027-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2023-06-08 with a primary completion date of 2027-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care. The main question it aims to answer is: How to find individuals unaffiliated from SCD specialist care use three distinct pathways? Once unaffiliated individuals are found using the pathways, Investigators will employ linkage coordinators (trained staff) to engage these patients in care. Participants will be asked to fill out an assessment survey which will cover areas such as previous and current treatment, clinic and hospital experience, pain, and quality of life. Participants will also be given the option of participation in a 1-hour long interview how they feel about treatment for sickle cell disease including clinic experience, pain, and quality of life?
Eligibility Criteria
Inclusion Criteria: * Persons must be \>/= 18 years of age * Persons must have confirmed SCD * Persons not seen by a SCD specialist \> 1 year +/- 3 months * Literacy in English will be required of the consenting patient or parent/guardian Exclusion Criteria: * Persons \< 18 years of age * Persons that are unable to provide informed consent and do not have a designated care-giver that can consent on his/her behalf * Persons with sickle cell trait (as per hemoglobin electrophoresis) * Persons seen by a SCD specialist \< 1 year +/1 3 months
Contact & Investigator
Julie Kanter, MD
PRINCIPAL INVESTIGATOR
University of Alabama, Birmingham (UAB)
Frequently Asked Questions
Who can join the NCT06385886 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06385886 currently recruiting?
Yes, NCT06385886 is actively recruiting participants. Contact the research team at lacox@rti.org for enrollment information.
Where is the NCT06385886 trial being conducted?
This trial is being conducted at Birmingham, United States, Phoenix, United States, Oakland, United States, Augusta, United States and 5 additional locations.
Who is sponsoring the NCT06385886 clinical trial?
NCT06385886 is sponsored by RTI International. The principal investigator is Julie Kanter, MD at University of Alabama, Birmingham (UAB). The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.